ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2399

Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization

Simran Bhimani1, Anand Maligireddy2, Shivang Chaudhary3, Yash Deshpande2, Kishan Patel4, Sameer Bhimani2, Shreyas Patel2 and Birju Bhatt5, 1The Wright Center for graduate medical education, Scranton, PA, 2The Wright Center, GME, Scranton, PA, 3Saint Louis University, St. Louis, MO, 4Riverside Community Hospital, Riverside, CA, 5Geisinger, Wilkes Barre, PA

Meeting: ACR Convergence 2024

Keywords:

Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Ischemic stroke poses significant risks for patients with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), both conditions associated with heightened cardiovascular complications. Endovascular Thrombectomy (EVT) is an essential treatment for acute ischemic stroke, yet its impact on these specific patient populations remains unclear. This study aims to evaluate the efficacy of EVT and its effects on demographics, comorbidities, mortality, and healthcare resource utilization in SLE and RA patients using data from the National Readmission Database.

Methods: We analyzed data from the National Readmission Database from 2016 to 2021, identifying 12,580 SLE and 54,364 RA patients admitted with ischemic stroke. The primary objective was to assess the role of EVT in these groups.

Results: SLE patients were younger (mean age 59.3 vs. 72.8 years, p < 0.05) and predominantly female (84.9% vs. 72.6%, p < 0.05) compared to RA patients. SLE patients had lower rates of cardiac arrhythmias (24.3% vs. 34.9%, p < 0.05) and hyperlipidemia (49.0% vs. 60.8%, p < 0.05) but higher rates of chronic kidney disease (24.1% vs. 20.1%, p < 0.05). Mortality rates for EVT were similar between the groups (both 11.3%, p = 0.9774), but RA patients without EVT had higher overall mortality (0.04% vs. 0.03%, p < 0.05). Hospital charges and lengths of stay were significantly higher for SLE patients both with EVT ($239,783 vs. $208,710, p < 0.05; 11.99 days vs. 10.15 days, p < 0.05) and without EVT ($82,364 vs. $67,414, p < 0.05; 6.72 days vs. 5.86 days, p < 0.0

Conclusion: While EVT mortality rates are similar for SLE and RA patients, RA patients without EVT exhibit higher overall mortality. SLE patients face greater healthcare burdens, reflected in higher hospital charges and longer lengths of stay. These findings highlight the need for tailored management strategies to address the unique challenges of each condition.

Supporting image 1

Supporting image 2

Disclosures: S. Bhimani: None; A. Maligireddy: None; S. Chaudhary: None; Y. Deshpande: None; K. Patel: None; S. Bhimani: None; S. Patel: None; B. Bhatt: None.

To cite this abstract in AMA style:

Bhimani S, Maligireddy A, Chaudhary S, Deshpande Y, Patel K, Bhimani S, Patel S, Bhatt B. Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/nationwide-analysis-of-endovascular-thrombectomy-in-ischemic-stroke-patients-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis-mortality-and-healthcare-utilization/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nationwide-analysis-of-endovascular-thrombectomy-in-ischemic-stroke-patients-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis-mortality-and-healthcare-utilization/